Don't Stop Believing: Teva's R&D Head Gives 3 Reasons Why Investors Should Hold On Post author:Sam Post published:November 15, 2017 Post category:BioPharma Teva’s stock jumped as investors get more hopeful about the future. Source: BioSpace You Might Also Like FDA Calls Bay Area Zogenix's Dravet Syndrome Drug a Breakthrough February 5, 2018 Neothetics to Slash an Unknown Number of Jobs, Review Strategic Alternatives July 10, 2017 Boston's InSpire MD Eyes $24.8 Million Series C Round January 25, 2017
